Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease

Abstract

Purpose: To investigate the clinical efficacy of montelukast/budesonide formoterol powder inhalation in treating chronic obstructive pulmonary disease (COPD) and its impact on serum high-sensitivity Creactive protein (hs-CRP), cancer antigen 125 (CA-125), and interleukin (IL)-6 levels.Methods: In total, 86 COPD patients treated in the clinic of Department of Respiratory Medicine inYichun People’s Hospital between December 2019 and December 2020 were recruited and randomly assigned to group A and group B alternately at the point of admission. Group B received conventional treatment, while group A was treated with conventional treatment plus montelukast/ budesonide formoterol powder inhalation.Results: Patients receiving montelukast /budesonide formoterol powder inhalation showed lower scores for cough, sputum, and shortness of breath, compared conventional treatment (p < 0.001). Patients in group A showed lower serum levels of hs-CRP, CA-125, and IL-6 after treatment than those in group B (p < 0.05). Pulmonary function and arterial blood gas indices were significantly different between the two groups after treatment (p < 0.05). Montelukast /budesonide formoterol powder inhalation resulted in higher Generic Quality Of Life Inventory-74 (GQOLI-74) scores and 6-min walking distance (6MWD) scores in patients than conventional treatment (p < 0.001). Also, Group A had a lower incidence of adverse reactions than group B (p < 0.05).Conclusion: Montelukast/budesonide formoterol powder inhalation has a better therapeutic effect versus conventional treatment, and improves patients' lung function and exercise tolerance. Further clinical trials are, however, required prior to general use in clinical practice.